510(k) Summary

Angelus Indústria de Produtos Odontológicos S/A

MTA Angelus K112046

December 27, 2011

ADMINISTRATIVE INFORMATION

Manufacturer Name: Angelus Indústria de Produtos Odontológicos S/A

> Rua Waldir Landgraf, 101 Londrina - PR - 86031-218

Brazil

Telephone: +55 (43) 2101-3200

Fax: +55 (43) 2101-3201

Official Contact: Marco Canonico

International Business Director

Representative/Consultant: Linda K. Schulz

Kevin A. Thomas

PaxMed International, LLC

11234 El Camino Real, Suite 200

San Diego, CA 92130

Telephone: +1 (858) 792-1235

+1 (858) 792-1236 Fax: Email: lschulz@paxmed.com

kthomas@paxmed.com

DEVICE NAME AND CLASSIFICATION

Trade/Proprietary Name: MTA Angelus

Classification Name: Root Canal Filling Resin

Classification Regulations: 21 CFR 872.3820, Class II

Product Code: KIF

Classification Panel: Dental Products Panel Reviewing Branch:

Dental Devices Branch

K112046

510(k) Summary MTA Angelus

INTENDED USE

 Treatment of perforations of root canal and furcation caused iatrogenically or by caries lesions

- Via canal treatment of root perforation due to internal resorption
- Surgical treatment of root perforation due to internal resorption
- · Periapical surgery with reverse filling
- Pulp capping
- Pulpotomy (removal of affected coronal pulp to preserve vitality of remaining pulp tissue)
- Apexogenesis (induction of root development in vital teeth with an inflamed coronal pulp).
- Apexification (induction of formation of a mineralized barrier at the root tip of young permanent teeth with incomplete root development and a necrotic pulp)

DEVICE DESCRIPTION

MTA Angelus is a mineral trioxide aggregate cement used for root repair during endodontic treatment, combining the powder and liquid produces a colloidal gel that solidifies to form a barrier.

EQUIVALENCE TO MARKETED DEVICE

Angelus Indústria de Produtos Odontológicos S/A demonstrated that, for the purposes of FDA's regulation of medical devices, MTA Angelus is substantially equivalent in indications and design principles to the following predicate devices:

DENTSPLY International, MTA Advanced Material cleared under K073218 and DENTSPLY International, White MTA Material cleared under K011009. DENTSPLY International, MTA Root Canal Sealer K080203

The subject device and the predicate devices have the same or similar intended use and have the same technological characteristics and are made of the same or similar materials. They encompass the same range of physical and chemical properties. The subject and predicate devices are packaged in similar materials and use similar methods of application. Any differences in the technological characteristics do not raise new issues of safety or efficacy.

Performance testing was conducted for setting time, solubility, radiopacity and dimensional changes to demonstrate substantial equivalence and included methods described in ISO 6876 *Dental Root Canal Sealing Materials*.

Overall, MTA Angelus has the following similarities to the predicate devices:

- has the same or similar intended use,
- uses the same operating principle,
- incorporates the same basic design,
- incorporates the same or very similar materials, and
- has similar packaging.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Angelus Industria de Produtos Odontologicos S/A C/O Ms. Linda K. Schulz Regulatory Affairs PaxMed International, LLC 11234 El Camino Real, Suite 200 San Diego, California 92130

JAN - 6 2012

Re: K112046

Trade/Device Name: MTA Angelus Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin

Regulatory Class: II Product Code: KIF

Dated: December 27, 2011 Received: December 28, 2011

Dear Ms. Schulz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and

Radiological Health

Who for

Indications for Use

K112046

510(k) Number:		
Devic	e Name:	MTA Angelus	
Indica	tions for Use:		
les Vi Su Pe Pu Aj	Periapical surgery with reverse filling Pulp capping Pulpotomy (removal of affected coronal pulp to preserve vitality of remaining pulp tissue) Apexogenesis (induction of root development in vital teeth with an inflamed coronal pulp)		
. (se <u>X</u> 301 Subpart D) AND/OR Over-The- (21 CFR 8) OT WRITE BELOW THIS LINE-CONTINUE ON	Counter Use 01 Subpart C) ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)			
		(Division Sign-Off)	Page 1 of
•		Division of Anesthesiology, General Hospit Infection Control, Dental Devices	al
		510(k) Number: 112046	